American Biogenetic backs thrombosis risk test:
This article was originally published in Clinica
Executive Summary
American Biogenetic Sciences has reached agreement with New Horizons Diagnostics to develop NHD's prototype Thrombus Precursor Protein (TpP) point of care test for soluble fibrin, a blood clot precursor. The in vitro test could be used for risk assessment of thrombosis and as a monitor during anti-coagulant therapies. ABS, based in Copiague, New York, also gains distribution rights to Columbia, Maryland-based NHD's other products.